期刊
ONCOTARGETS AND THERAPY
卷 10, 期 -, 页码 31-34出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S115892
关键词
large granular lymphocytes; lymphoproliferative; Felty; neutropenia; bortezomib
资金
- Romanian National Authority for Scientific Research, CNCS - UEFISCDI [PN-II-RU-TE-2014-4-2074]
Large granular lymphocytic leukemia (LGLL) is a rare lymphoproliferative disorder of transformed natural killer or T-cells attributed to chronic exposure to the proinflammatory cytokine IL-15. Diagnosis of the majority of T-cell LGLL is established by documenting clonal large granular lymphocytes (LGLs) in peripheral blood, by morphology and immunophenotype. The proteasome inhibitor bortezomib is known to target molecular pathways downstream of the IL-15 receptor signaling and has been proposed as a therapy in these patients. We report an uncommon presentation of LGLL with chronic neutropenia lacking typical blood LGLs, which failed to respond to bortezomib but obtained a very good partial remission with a classical methotrexate regimen.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据